Oppenheimer Asset Management Inc. Increases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Oppenheimer Asset Management Inc. boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 89,344 shares of the medical research company's stock after purchasing an additional 4,605 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Thermo Fisher Scientific were worth $44,458,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of TMO. LaFleur & Godfrey LLC lifted its position in Thermo Fisher Scientific by 9.1% during the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after purchasing an additional 2,488 shares in the last quarter. Brighton Jones LLC lifted its position in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $71,877,000. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG lifted its position in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after acquiring an additional 461 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 0.6%

Shares of NYSE:TMO traded up $2.38 during trading hours on Monday, hitting $400.26. 2,485,958 shares of the company's stock traded hands, compared to its average volume of 1,944,901. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The business has a fifty day moving average price of $411.66 and a 200-day moving average price of $486.42. The firm has a market capitalization of $151.09 billion, a P/E ratio of 23.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the previous year, the business earned $5.11 earnings per share. The company's revenue for the quarter was up .2% compared to the same quarter last year. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Analysts Set New Price Targets

TMO has been the topic of several research analyst reports. Scotiabank lowered their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research report on Friday, April 25th. Royal Bank Of Canada lowered their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Argus decreased their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Finally, Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $605.30.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.